JP7570342B2 - 眼の疾患又は障害を治療するための医薬組成物 - Google Patents

眼の疾患又は障害を治療するための医薬組成物 Download PDF

Info

Publication number
JP7570342B2
JP7570342B2 JP2021552571A JP2021552571A JP7570342B2 JP 7570342 B2 JP7570342 B2 JP 7570342B2 JP 2021552571 A JP2021552571 A JP 2021552571A JP 2021552571 A JP2021552571 A JP 2021552571A JP 7570342 B2 JP7570342 B2 JP 7570342B2
Authority
JP
Japan
Prior art keywords
depot
therapeutic agent
pharmaceutical composition
lactide
biodegradable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523548A5 (https=
JPWO2020181060A5 (https=
JP2022523548A (ja
Inventor
クマール ダス、サンジブ
リン、チェン－ウェン
Original Assignee
アエリエ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アエリエ ファーマシューティカルズ インコーポレイテッド filed Critical アエリエ ファーマシューティカルズ インコーポレイテッド
Publication of JP2022523548A publication Critical patent/JP2022523548A/ja
Publication of JP2022523548A5 publication Critical patent/JP2022523548A5/ja
Publication of JPWO2020181060A5 publication Critical patent/JPWO2020181060A5/ja
Priority to JP2024176400A priority Critical patent/JP7852008B2/ja
Priority to JP2024176401A priority patent/JP7838047B2/ja
Application granted granted Critical
Publication of JP7570342B2 publication Critical patent/JP7570342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Biological Depolymerization Polymers (AREA)
JP2021552571A 2019-03-05 2020-03-05 眼の疾患又は障害を治療するための医薬組成物 Active JP7570342B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024176400A JP7852008B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物
JP2024176401A JP7838047B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814198P 2019-03-05 2019-03-05
US62/814,198 2019-03-05
PCT/US2020/021136 WO2020181060A1 (en) 2019-03-05 2020-03-05 Pharmaceutical compositions for treating ocular diseases or disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2024176401A Division JP7838047B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物
JP2024176400A Division JP7852008B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物

Publications (4)

Publication Number Publication Date
JP2022523548A JP2022523548A (ja) 2022-04-25
JP2022523548A5 JP2022523548A5 (https=) 2023-03-08
JPWO2020181060A5 JPWO2020181060A5 (https=) 2023-03-08
JP7570342B2 true JP7570342B2 (ja) 2024-10-21

Family

ID=72337143

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552571A Active JP7570342B2 (ja) 2019-03-05 2020-03-05 眼の疾患又は障害を治療するための医薬組成物
JP2024176401A Active JP7838047B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024176401A Active JP7838047B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物

Country Status (10)

Country Link
US (2) US12478577B2 (https=)
EP (1) EP3934646A4 (https=)
JP (2) JP7570342B2 (https=)
KR (1) KR20210135560A (https=)
CN (3) CN118304422A (https=)
AU (1) AU2020232314C1 (https=)
BR (1) BR112021017436A2 (https=)
CA (1) CA3132635A1 (https=)
MX (2) MX2021010599A (https=)
WO (1) WO2020181060A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021010599A (es) 2019-03-05 2021-12-10 Aerie Pharmaceuticals Inc Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares.
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
EP3884929B1 (en) 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
WO2021207486A1 (en) * 2020-04-08 2021-10-14 Aerie Pharmaceuticals, Inc. Treatments
CA3218251A1 (en) 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
WO2022235906A1 (en) 2021-05-05 2022-11-10 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物
WO2025146683A1 (en) 2024-01-03 2025-07-10 Lyotropic Delivery Systems Ltd. Topical formulations for delivery of an active compound to the back of the eye
WO2025169089A1 (en) 2024-02-05 2025-08-14 Sun Pharmaceutical Industries Limited Ophthalmic compositions of tyrosine kinase inhibitors and their uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012150255A1 (en) 2011-05-02 2012-11-08 Dsm Ip Assets B.V. Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
JP2014184348A (ja) 2008-11-17 2014-10-02 Allergan Inc 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途
JP2016502608A (ja) 2012-10-24 2016-01-28 ディーエスエム アイピー アセッツ ビー．ブイ． 薬物送達のためのポリエステルアミドコポリマーを含む繊維
JP2016515618A (ja) 2013-04-01 2016-05-30 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続的眼内放出のためのマイクロスフェア薬剤送達システム
JP2017537903A (ja) 2014-12-18 2017-12-21 ディーエスエム アイピー アセッツ ビー．ブイ． 酸感受性薬剤の送達のための薬剤送達系

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649672C (en) * 2006-05-02 2015-07-07 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
JP2011518812A (ja) * 2008-04-25 2011-06-30 ディーエスエム アイピー アセッツ ビー．ブイ． チオエステル結合を有するポリマーを含む粒子
EP2587304B1 (en) * 2010-06-22 2019-12-18 Toyobo Co., Ltd. Liquid crystal display device, polarizer and protective film
BR112013018739A2 (pt) * 2010-12-29 2019-09-24 Jade Therapeutics Inc sistema de distribuição de medicamento ocular
JP6135870B2 (ja) * 2011-05-02 2017-05-31 ディーエスエム アイピー アセッツ ビー．ブイ． 生分解性ポリマーを含む繊維
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
CA2881729C (en) 2012-10-02 2021-05-04 Dsm Ip Assets B.V. Drug delivery composition comprising proteins and biodegradable polyesteramides
CN109602691A (zh) * 2013-02-15 2019-04-12 阿勒根公司 持续药物递送植入物
WO2015126477A1 (en) 2013-11-08 2015-08-27 Tyrx, Inc. Polymeric drug delivery system for treating surgical complications
MX2016007345A (es) * 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
WO2015095772A2 (en) * 2013-12-20 2015-06-25 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
CN109481447A (zh) * 2014-09-06 2019-03-19 整体生物系统有限责任公司 用于在眼中实现持续药物释放的方法和生物相容性组合物
EP3324944A4 (en) 2015-07-23 2019-04-03 Aerie Pharmaceuticals, Inc. INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
WO2017120600A1 (en) 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Compositions and methods of treating wet age-related macular degeneration
US20180117148A1 (en) * 2016-10-28 2018-05-03 Andrew J. Holman Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
WO2018161035A1 (en) * 2017-03-03 2018-09-07 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
MX2021010599A (es) 2019-03-05 2021-12-10 Aerie Pharmaceuticals Inc Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014184348A (ja) 2008-11-17 2014-10-02 Allergan Inc 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途
WO2012150255A1 (en) 2011-05-02 2012-11-08 Dsm Ip Assets B.V. Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
JP2016502608A (ja) 2012-10-24 2016-01-28 ディーエスエム アイピー アセッツ ビー．ブイ． 薬物送達のためのポリエステルアミドコポリマーを含む繊維
JP2016515618A (ja) 2013-04-01 2016-05-30 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続的眼内放出のためのマイクロスフェア薬剤送達システム
JP2017537903A (ja) 2014-12-18 2017-12-21 ディーエスエム アイピー アセッツ ビー．ブイ． 酸感受性薬剤の送達のための薬剤送達系

Also Published As

Publication number Publication date
KR20210135560A (ko) 2021-11-15
MX2025002265A (es) 2025-04-02
CN118286445A (zh) 2024-07-05
CN118304422A (zh) 2024-07-09
AU2020232314C1 (en) 2024-03-28
BR112021017436A2 (pt) 2021-11-16
JP2022523548A (ja) 2022-04-25
AU2020232314A1 (en) 2021-09-30
AU2020232314B2 (en) 2023-10-12
CN113784727A (zh) 2021-12-10
JP7838047B2 (ja) 2026-03-31
US20260034056A1 (en) 2026-02-05
CA3132635A1 (en) 2020-09-10
JP2025004160A (ja) 2025-01-14
JP2025004161A (ja) 2025-01-14
US20200306182A1 (en) 2020-10-01
EP3934646A1 (en) 2022-01-12
US12478577B2 (en) 2025-11-25
WO2020181060A1 (en) 2020-09-10
MX2021010599A (es) 2021-12-10
CN113784727B (zh) 2024-03-29
EP3934646A4 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
JP7570342B2 (ja) 眼の疾患又は障害を治療するための医薬組成物
JP5552102B2 (ja) 長時間放出特性を有する生分解性眼インプラント
JP5608138B2 (ja) 生分解性チロシンキナーゼインヒビター硝子体内インプラント
US11116776B2 (en) Intravitreal drug delivery systems for the treatment of ocular conditions
TWI377956B (en) Biodegradable intravitreal tyrosine kinase implants
JP6570513B2 (ja) 持続的眼内放出のためのマイクロスフェア薬剤送達システム
JP2009535422A (ja) 血管作動薬を含有する持続放出性眼内インプラント
JP2016540055A (ja) 眼性状態を処置するための前房内インプラント
JP2013035874A (ja) α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
JP7852008B2 (ja) 眼の疾患又は障害を治療するための医薬組成物
CN120897764A (zh) 包含阿西替尼多晶型物iv的眼部植入物
BRPI0604577B1 (pt) formulação farmacêutica para administração intraocular de fármacos e processo de obtenção
AU2016269432A1 (en) Biodegradable introcular tyrosine kinase inhibitor implants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241008

R150 Certificate of patent or registration of utility model

Ref document number: 7570342

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350